• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Decapeptyl CR 3.75
    / Ferring Pharmaceuticals

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Controlled-Release Microcapsules

    3.75 mg

    partial basket chart 13755 4512

    Related information


    Initially, Decapeptyl 0.5 mg is administered once a day for 7 days. From the 8th day on, Decapeptyl 0.1 mg is administered once a day. Alternatively, Decapeptyl Depot (3.75 mg triptorelin as a controlled-release preparation for IM application once every 28 days) is available.


    Precocious puberty, prostate cancer, endometriosis, uterusleiomyoma, I.V.F.


    Proven hormone-independence of the carcinoma. Following surgical castration, treatment induces no further fall in the testosterone level. Known hypersensitivity to triptorelin, poly(glycolic acid, lactic acid), dextran or any other component.
    Pregnancy and lactation: Situations where maintenance of endogenous sex hormone activity is essential.

    Special Precautions

    Prostatic carcinoma patients with impending spinal cord compression or severe urinary tract disorders. Premenstrual syndrome (exacerbation of symptoms). Renal insufficiency. Bone loss has been reported in some studies during long-term therapy in women with endometriosis or uterine leiomyoma. Paralysis arising from a transient activation of the tumor and its metastases. In hypertensive patients, blood pressure must be monitored regularly. In diabetic patients, blood sugar levels must be checked regularly. Patients with a history of depression must be carefully monitored. Operating a vehicle or machinery.

    Side Effects

    Short-term in serum testosterone, occurrence of or increase in bone pain, obstruction of the urinary tract and its sequelae, contusion of the spinal cord, muscular weakness in the legs, lymphatic edema. Withdrawal frequently results in hot flushes with profuse sweating and with loss of libido and potency. Less frequent: gynecomastia, testicular atrophy and sleeplessness have been reported. Hypersensitivity reactions. Endocrine effects, CNS effects, genitourinary effects.
    See prescribing information for full details.

    Drug interactions

    None known.

    Ferring Pharmaceuticals Israel